Skip to main content
RIBOMIC Inc. logo

RIBOMIC Inc. — Investor Relations & Filings

Ticker · 4591 ISIN · JP3974850004 T Manufacturing
Open in API
Filings indexed 74 across all filing types
Latest filing 2026-06-09 Regulatory Filings
Country JP Japan
Listing T 4591

About RIBOMIC Inc.

https://www.ribomic.com/eng/

RIBOMIC Inc. is a biopharmaceutical company engaged in the discovery and development of novel molecular-targeted therapeutics using its proprietary RNA aptamer technology. The company's core drug discovery platform, the RiboART System (Ribomic Aptamer Refined Therapeutics System), enables the creation of aptamers that bind to target molecules with high affinity and specificity. RIBOMIC's development pipeline focuses on addressing significant unmet medical needs in various therapeutic areas. Key clinical programs include potential treatments for ophthalmic conditions, such as wet age-related macular degeneration, and rare genetic disorders like achondroplasia.

Recent filings

Filing Released Lang Actions
東京大学との共同研究における進捗および契約期間延長に関するお知らせ
Regulatory Filings Classification · 90% confidence The document is a corporate announcement regarding progress and contract extension of a collaborative research project with the University of Tokyo. It contains no financial statements, no voting results, no dividends, no share transactions, no regulatory forms, and does not present an actual report but rather a project update. This falls under the fallback category for miscellaneous regulatory announcements (RNS).
2026-06-09 Japanese
第三者割当により発行された第19回新株予約権（行使価額修正条項付）の行使停止指定に関するお知らせ
Capital/Financing Update Classification · 82% confidence The document is a corporate disclosure announcing the designation of an exercise suspension for the company’s 19th stock acquisition rights (warrants) issued by third-party allotment. It details the capital instrument, dates, and numbers, and pertains to a change in the company’s capital structure. This falls under capital/financing updates (CAP).
2026-06-08 Japanese
軟骨無形成症治療薬（umedaptanib pegol）の国内第III相臨床試験におけるIRB（治験審査委員会）承認のお知らせ
Regulatory Filings Classification · 93% confidence The document is a corporate announcement by Ribomic Corporation (code 4591) regarding the IRB (Institutional Review Board) approval for a domestic Phase III clinical trial of their treatment candidate. It contains no financial statements, earnings data, or investor materials. It is a general regulatory announcement about trial approval submitted to the exchange, thus it does not fit into specific financial report categories (e.g., 10-K, ER, IR) nor governance or corporate action categories (e.g., AGM, DIRS, M&A). Therefore, it falls under the fallback “Regulatory Filings” category.
2026-06-03 Japanese
第三者割当により発行された第19回新株予約権（行使価額修正条項付）の月間行使状況に関するお知らせ
Share Issue/Capital Change Classification · 85% confidence The document is an official announcement detailing the monthly exercise status of the company’s share subscription rights (new stock warrants) issued by a third-party allotment, including the number of warrants exercised, shares issued, and outstanding amounts. This is a direct report of a capital change (issuance of new shares upon warrant exercise), fitting the definition of a Share Issue/Capital Change (SHA).
2026-06-01 Japanese
資本金及び資本準備金の額の減少並びに剰余金の処分に関するお知らせ
Share Issue/Capital Change Classification · 85% confidence The document is a formal notice announcing the board’s decision to propose a reduction in share capital and capital reserves and the appropriation of surplus at the upcoming shareholders’ meeting. It details changes in capital stock amounts, reserve transfers, and the schedule for creditor objection and effectiveness. This is clearly a capital change announcement rather than an actual financial report, management commentary, or unrelated regulatory filing. Therefore, it fits the “Share Issue/Capital Change” category (Code: SHA).
2026-05-20 Japanese
会計監査人の異動に関するお知らせ
Regulatory Filings Classification · 85% confidence The document is a corporate disclosure titled “会計監査人の異動に関するお知らせ,” notifying shareholders of the proposed change of the external accounting auditor at the upcoming shareholders’ meeting. It contains no financial statements or audit opinions itself, and it is an announcement of an auditor appointment/retirement, not the audit report. There is no specific category for auditor changes, so it falls under miscellaneous regulatory announcements.
2026-05-20 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.